×HomeScreening and diagnosis of type 2 diabetesGlycaemic monitoring and targets for type 2 diabetesLifestyle managementNon-insulin medicationsInsulinScreening and management of complications of diabetesManagement of cardiovascular risk factors in diabetesManagement of hypoglycaemiaSick day managementDiabetes in pregnancyDiabetes and drivingPrediabetesGo to the NZSSD site
Page updated: 12 December 2023

Pharmac have temporarily changed the special authority for GLP1 receptor agonists (GLP1RA; dulaglutide and liraglutide) because of the worldwide shortage of GLP1RA to the below:

following funded glucose lowering agents for a period of at least 6 months, where clinically, appropriate, empagliflozin, metformin and vildagliptin AND EITHER

Please note that the change was made without full clinical consultation and we understand that the new special authority criteria may lead to confusion. To maintain consistent supply of GLP1RA we recommend:

- Ensuring that GLP1RA are used only for glycaemic control and not for weight loss 

- To not switch between dulaglutide (Trulicity) and liraglutide (Victoza)

We always recommend best practice and it is important that those who need GLP1RA the most receive GLP1RA, particularly those with type 2 diabetes and cardiovascular disease. For these patients, we do not recommend trialling and/or persisting with alternative glucose lowering therapies if clinically inappropriate and/or if ongoing adverse effects. But we all have a responsibility to be clinically judicious and we continue to work with PHARMAC on possible solutions such as dual funded empagliflozin with GLP1RA, funded GP visits and pharmacy education etc., but this is a work in progress and we continue to provide an update on this page.